Shell has spent several years and nearly $6 billion on its Arctic campaign thus far. Harsh conditions, poor infrastructure, and a short drilling season hindered its progress, but it could be returning to the Arctic after a two-year hiatus.
Exelixis stock takes one on the chin after the company's lead compound fails to provide a statistically significant survival benefit in a late stage prostate cancer trial. Find out what's next for this highly-followed biotech stock.
Beijing is pressing unpopular changes to Hong Kong's election laws that some say threaten to undermine the pillars that have made the city a commercial success at the doorstep of the world's second-biggest economy.